Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
Date:2/21/2013

THE WOODLANDS, Texas, Feb. 21, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2012.

"We continued to make significant progress in the development of our pipeline in 2012, highlighted by positive results from clinical studies of LX4211 in diabetes and telotristat etiprate in carcinoid syndrome," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. "We are pleased to have commenced the Phase 3 program for telotristat etiprate in carcinoid syndrome, and continue to progress in our preparations for LX4211 Phase 3 initiation. We also look forward to significant proof-of-concept results in irritable bowel syndrome (IBS) with LX1033, ulcerative colitis with telotristat etiprate, and type 1 diabetes with LX4211 in 2013."

Key Developments in 2012

  • LX4211:  Lexicon reported positive results from a 12-week Phase 2b clinical trial of LX4211, a dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2) in patients with type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy. LX4211 treatment produced substantial, dose-dependent and statistically-significant reductions in hemoglobin A1c (HbA1c), with patients in the high dose (400 mg QD) LX4211 treatment arm having a mean HbA1C reduction from baseline of 0.95 percent (p<0.001). In patients randomized to placebo, HbA1C decreased by 0.09 percent. LX4211 treatment also produced significant reduct
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Lexicon To Present At The BIO CEO & Investor Conference
    2. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
    3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
    4. Lexicon to Provide Third Quarter 2012 Financial Results
    5. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
    6. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
    7. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
    8. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
    9. Lexicon to Provide Second Quarter 2012 Financial Results
    10. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
    11. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/30/2015)... TOKYO , May 30, 2015  Astellas Pharma ... a Phase 1/2 trial on the safety, tolerability and ... patients with relapsed or refractory (R/R) acute myeloid leukemia ... the American Society of Clinical Oncology,s (ASCO) annual meeting ... is a receptor tyrosine kinase inhibitor of FLT3 and ...
    (Date:5/30/2015)... Tex. , May 30, 2015 ... on fulfilling the promise of precision medicine, today ... that demonstrate the utility of Caris Molecular Intelligence®, ... facilitating comparisons between tumors that share histological features. ... the American Society of Clinical Oncology (ASCO) in ...
    (Date:5/29/2015)... 2015  Excite Medical was established by its President, ... Excite Medical, under the leadership of Mr. Musallam ... a solid track record of providing unparalleled service and ... base.  Photo - http://photos.prnewswire.com/prnh/20150529/219412 ... been possible, in large part, due to Mr. ...
    Breaking Medicine Technology:Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) 2Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) 3Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 2Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 3Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 4Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 5Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 6
    (Date:5/30/2015)... Chicago, Ill. (PRWEB) May 30, 2015 ... academicians were recognized by their peers as the 2015 ... hosted by OncLive® at the Chicago Illuminating Company last ... panel of eminent oncologists for landmark achievements in translational ... has changed the course of cancer treatment. , Honorees ...
    (Date:5/30/2015)... 2015 Thousands of aesthetic industry professionals ... sponsored by the American Society for Aesthetic Plastic Surgery ... was Zeltiq, the parent company of one of the ... With blazing growth, the one-of-a-kind device just sold its ... is currently in the news for gaining the FDA’s ...
    (Date:5/30/2015)... 30, 2015 On Thursday, May ... Charles Simone and Dr. Evan Alley both of ... the Mesothelioma Experts’ series. The interview was part ... centers of excellence. Drs. Simone and Alley were ... Hesdorffer, with whom they discussed the mesothelioma program ...
    (Date:5/30/2015)... Industry, CA (PRWEB) May 30, 2015 ... technology and foreign travelers who experienced OGAWA products while ... in the U.S. , A leader in the ... is a cutting-edge designer, researcher, developer and manufacturer of ... longevity and superior craftsmanship of their products, health enthusiasts ...
    (Date:5/30/2015)... Cyclist Barry Haarde will commence his ... 2015: Piles of Miles” near San Francisco, California ... and encourage individuals to support needy hemophilic children ... Life supports nearly 1,200 impoverished children and adults ... sponsorships, scholarships and micro-enterprise grants. Hemophilia is a ...
    Breaking Medicine News(10 mins):Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 2Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 3Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 4Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 3Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2
    ... placenta may damage blood vessels in women with preeclampsia ... to life-threatening increases in high blood pressure after 20 ... substances called "microparticles" released by the placenta damage maternal ... by Seth Guller, sought to detect whether specific proteins ...
    ... mutation that causes X-linked mental retardation for which there ... study. ,Investigators F. Lucy Raymond, ... Sanger Institute, UK describe the ZDHHC9 gene found in ... point of entirely losing function. ,"ZDHHC9 ...
    ... A new calibration technique that involves measuring the distance ... help facial plastic surgeons// use computer imaging software, according ... facial proportions has been studied for centuries by architects, ... information in the article. It is essential for plastic ...
    ... who treat them have incorporated spirituality into the recovery ... how spirituality changes during recovery, or how those changes ... quest for sobriety. ,Now, a new study ... Center sheds light on this phenomenon. In the March ...
    ... developed a malaria-resistant mosquito, a step that might one day ... millions// of lives around the world. ,When ... higher survival rate than nonresistant ones, meaning they could eventually ... a report in Tuesday's issue of Proceedings of the National ...
    ... by the National Aeronautics and Space Administration (NASA) has ... has been thinning// since early 1990s. ,Aerosols ... naturally, originating from volcanoes, dust storms, forest and grassland ... tend to cause cooling of the Earth's surface immediately ...
    Cached Medicine News:Health News:Severe Mental Retardation Gene Mutation Identified 2Health News:Computer Imaging Assists With Facial Reconstructive Surgery 2Health News:Spirituality Increases as Alcoholics Recover 2Health News:Spirituality Increases as Alcoholics Recover 3Health News:Malaria-resistant Mosquito Developed 2
    ... laser beam is delivered through an ultra thin ... the operator full freedom of movement when performing ... with a wide range of handpieces. Handpieces ... mm and 16 mm. Straight and angled ...
    These are the Reusable Components (minus cannula), to be used with the VersaStep™ Plus Reposable Short System....
    ... VERSASTEP™ Plus Short Instrument for ... ,The VERSASTEP™ Plus Short ... Length is a unique endoscopic ... in laparoscopic procedures. It is ...
    ... Autosuture™ Blunt Tip Trocar consists of a ... a valve body assembly. , ,The ... valve and seal to prevent gas leakage ... Autosuture™ Blunt Tip Trocar includes built-in converters ...
    Medicine Products: